GlassScriptPhysician profile
Sylvia P Shoffner
NPI 1912049669
$1,871.33
in general payments reported to CMS, 2019-2025
29 companies · $75.95 in 2025
The $75.95 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.19 · 2021: $37.17 · 2022: $12.80 · 2023: $1,593 · 2024: $88.16 · 2025: $75.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $943 · Food and Beverage: $814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $942.83 |
| Food and Beverage | $814.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim International Gmbh | $1,432.83 | 2023 | |
| Abbott Laboratories | $113.32 | 2023-2025 | Freestyle Libre 3, Octrode |
| Astellas Pharma US INC | $55.26 | 2019-2024 | Veozah |
| Abbvie INC. | $48.00 | 2023-2025 | Ubrelvy |
| Pfizer INC. | $45.16 | 2019-2024 | |
| Novo Nordisk INC | $24.34 | 2023 | Wegovy, Saxenda |
| Exact Sciences Corporation | $20.05 | 2023 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $19.50 | 2024 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.87 | 2025 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $17.24 | 2023 | Quviviq |
| Esperion Therapeutics, INC. | $17.17 | 2021 | |
| Lilly USA, LLC | $17.00 | 2023 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $16.83 | 2019 | |
| Amgen INC. | $12.96 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.80 | 2022 |
14 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sylvia Shoffner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.